Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,643,412
  • Shares Outstanding, K 79,816
  • Annual Sales, $ 77,470 K
  • Annual Income, $ -178,840 K
  • 60-Month Beta 1.44
  • Price/Sales 22.12
  • Price/Cash Flow N/A
  • Price/Book 5.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.60
  • Number of Estimates 6
  • High Estimate -0.48
  • Low Estimate -0.69
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -22.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.40 +19.20%
on 10/15/19
22.20 -6.58%
on 11/04/19
+2.84 (+15.90%)
since 10/11/19
3-Month
16.60 +24.94%
on 08/28/19
22.20 -6.58%
on 11/04/19
+2.66 (+14.71%)
since 08/12/19
52-Week
15.68 +32.27%
on 08/07/19
29.49 -29.67%
on 12/04/18
-6.81 (-24.72%)
since 11/12/18

Most Recent Stories

More News
Look for Shares of Heron Therapeuti to Potentially Pullback after Yesterday's 20.96% Rise

Heron Therapeuti (NASDAQ:HRTX) traded in a range yesterday that spanned from a low of $20.65 to a high of $21.61. Yesterday, the shares gained 21.0%, which took the trading range above the 3-day high...

HRTX : 20.74 (+0.73%)
Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 30.00% and 25.64%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

HRTX : 20.74 (+0.73%)
Heron Therapeutics: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Tuesday reported a loss of $33.6 million in its third quarter.

HRTX : 20.74 (+0.73%)
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important...

HRTX : 20.74 (+0.73%)
Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important...

HRTX : 20.74 (+0.73%)
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important...

HRTX : 20.74 (+0.73%)
Pfenex Inc has the Best Relative Performance in the Biotechnology Industry (PFNX, HRTX , NTRA , FLXN , ARWR)

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

HRTX : 20.74 (+0.73%)
NTRA : 39.01 (+4.47%)
PFNX : 9.74 (-6.79%)
ARWR : 45.28 (+5.45%)
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, In. (NASDAQ: HCSG), Heron Therapeutics, Inc. (NASDAQ: HRTX), Immunomedics, Inc. (NASDAQ: IMMU), and Karyopharm...

HCSG : 25.22 (-1.52%)
HRTX : 20.74 (+0.73%)
IMMU : 17.40 (+1.16%)
KPTI : 15.44 (+1.05%)
Heron Therapeutics Announces Pricing of Public Offering of Common Stock

Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most...

HRTX : 20.74 (+0.73%)
Heron Therapeutics Announces Proposed Public Offering of Common Stock

Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most...

HRTX : 20.74 (+0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade HRTX with:

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

2nd Resistance Point 22.07
1st Resistance Point 21.41
Last Price 20.74
1st Support Level 20.34
2nd Support Level 19.93

See More

52-Week High 29.49
Fibonacci 61.8% 24.21
Fibonacci 50% 22.58
Fibonacci 38.2% 20.96
Last Price 20.74
52-Week Low 15.68

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar